Clinical Trial Update: Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial called iRITUX is testing AI-guided, personalized rituximab treatment for membranous nephropathy. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Membranous Nephropathy | Phase 3 | Status: RECRUITING